Neurofibromatosis is diagnosed primarily through a clinical evaluation, meaning a doctor looks for a specific combination of physical signs rather than relying on a single test. For the most common form, NF1, a diagnosis requires at least two features from a defined checklist, such as skin spots, freckling, or tumor growths. Genetic testing can confirm or support the diagnosis, but most cases are identified through a physical exam and family history.
The Three Types and Why It Matters
Neurofibromatosis isn’t a single condition. There are three main forms, each caused by changes in different genes, and each diagnosed differently. NF1 (formerly called von Recklinghausen disease) is the most common, affecting roughly 1 in 3,000 people. NF2-related schwannomatosis involves nerve tumors, particularly on the hearing and balance nerves. A third group, previously just called “schwannomatosis,” is now classified by the specific gene involved, such as SMARCB1 or LZTR1. A 2022 international update reorganized the naming system so that NF2 and the older “schwannomatosis” both fall under the umbrella term schwannomatosis, with subtypes defined by the affected gene.
How NF1 Is Diagnosed
For someone without a parent already diagnosed with NF1, the diagnosis requires two or more of the following features:
- Café-au-lait spots: Six or more flat, light-brown skin patches. In children before puberty, each spot must be larger than 5 mm across. In teens and adults, the threshold rises to 15 mm.
- Freckling in skin folds: Clusters of freckles in the armpits or groin area, present on both sides of the body.
- Neurofibromas: Two or more of these benign nerve tumors of any type, or one plexiform neurofibroma (a larger, deeper growth that develops along a nerve).
- Optic pathway glioma: A tumor along the nerve connecting the eye to the brain, detected by MRI.
- Lisch nodules or choroidal abnormalities: Two or more tiny, harmless bumps on the colored part of the eye, visible during a slit-lamp exam. Alternatively, two or more bright, patchy nodules in the deeper layers of the eye, detected with specialized imaging.
- Bone abnormalities: Distinctive skeletal findings like bowing of the shinbone or thinning of a specific skull bone.
- A confirmed NF1 gene variant: A pathogenic change in the NF1 gene found through blood testing.
If a child has a parent who already meets these criteria, only one feature is needed for diagnosis. One important caveat: when café-au-lait spots and freckling are the only findings, the diagnosis is most likely NF1, but a related condition called Legius syndrome can look almost identical at that stage. People with Legius syndrome do not develop the eye nodules, neurofibromas, or other complications of NF1, so those features help clinicians tell the two apart.
When Features Appear by Age
One of the challenges with NF1 is that not all signs show up at once. Café-au-lait spots are usually the earliest clue, often visible in infancy. Freckling tends to appear in early childhood. Skin neurofibromas, however, rarely develop in young children. They typically emerge around puberty or just before it, which means a young child might not yet meet the two-feature threshold based on a physical exam alone.
Lisch nodules follow a similar age-dependent pattern. About 50% of children with NF1 have them by age 5, rising to 75% by age 15 and 90 to 95% by age 30. Because these eye nodules are present in virtually all adults with NF1, they are considered the most consistent physical finding, but their absence in a young child doesn’t rule the condition out.
The Role of Eye Exams
A slit-lamp eye exam is a standard part of the NF1 workup. The doctor is looking for Lisch nodules, small raised bumps on the iris that are harmless but highly specific to NF1. Newer imaging techniques can also detect choroidal abnormalities, bright patchy spots in the deeper tissue of the eye, which are useful because they help distinguish NF1 from Legius syndrome with high accuracy.
Eye exams also screen for optic pathway gliomas. Annual eye checkups are recommended for children with NF1, since these tumors can affect vision gradually. If a child develops reduced vision, hormonal changes, or new neurological symptoms, a brain MRI is used to look for these growths. Routine “screening” MRIs for children who have no symptoms are not recommended, because many optic pathway gliomas never cause problems and discovering them incidentally can lead to unnecessary anxiety and treatment.
When MRI Is Used
MRI plays a targeted role in NF1 diagnosis and monitoring. It is the primary tool for detecting optic pathway gliomas, plexiform neurofibromas, and other internal tumors that aren’t visible on a skin exam. When a symptomatic optic pathway glioma is found, follow-up MRIs are typically done every 3 months for the first year, then every 6 months for the next two years. If things remain stable, the interval stretches to annual scans, continuing until age 18.
For NF2-related schwannomatosis, MRI is even more central to diagnosis. The hallmark finding is tumors on the hearing and balance nerves (vestibular schwannomas), often on both sides. MRI of the brain and spine can also reveal other nerve tumors or spinal cord growths called ependymomas, which factor into the diagnostic criteria.
Genetic Testing
Genetic testing isn’t always necessary when the clinical signs clearly point to NF1, but it can be valuable in several situations: when a young child has café-au-lait spots but hasn’t yet developed a second feature, when the diagnosis is uncertain, or when a family wants information for reproductive planning. Modern testing protocols identify the disease-causing NF1 gene variant in about 95% of people who meet the clinical criteria, making it a highly reliable confirmation tool.
For families where one parent has a known NF1 variant, prenatal testing is available. Chorionic villus sampling can be performed as early as 11 weeks of pregnancy, while amniocentesis is typically done between 15 and 16 weeks. In one large study of over 200 prenatal tests, about 88% used chorionic villus sampling, reflecting its earlier timing and reliability. One complication that can arise is germline mosaicism, where the parent carries the gene change in only some of their cells, which can make results harder to interpret.
Diagnosing NF2 and Other Schwannomatosis Types
NF2-related schwannomatosis is diagnosed using a different set of criteria than NF1. The classic presentation is bilateral vestibular schwannomas, tumors on the hearing nerves on both sides, which typically cause hearing loss, ringing in the ears, or balance problems. However, not everyone with NF2 develops bilateral tumors, and updated criteria from 2019 and 2022 have improved detection for those patients. The current criteria also factor in other tumor types like ependymomas and incorporate molecular testing.
For the subtypes previously grouped as “schwannomatosis,” diagnosis involves finding multiple nerve sheath tumors (schwannomas) without the bilateral vestibular schwannomas that define NF2. Genetic testing plays a larger role here, since identifying the specific gene involved (SMARCB1, LZTR1, or changes on chromosome 22q) determines the exact subtype. When no known gene change is found, the diagnosis may be classified as schwannomatosis-NOS (not otherwise specified).
What to Expect During the Diagnostic Process
For most people, the process starts with a thorough skin exam. A doctor will count café-au-lait spots, measure their size (often with a simple ruler), and check for freckling in skin folds. They will feel for any lumps under or on the skin that could be neurofibromas. A slit-lamp eye exam is typically part of the initial evaluation. Depending on what’s found, the doctor may order an MRI or refer you for genetic testing.
In children, the process can stretch over months or even years, since features appear at different ages. A toddler with multiple café-au-lait spots but no other signs may be monitored with periodic checkups rather than given a definitive diagnosis right away. Genetic testing can accelerate this timeline by identifying a gene variant before the second clinical feature appears, which can be especially helpful for early monitoring and planning.